Public Health Agency of Canada / Office de la santé public du Canada
Skip first menu Skip all menus Français Contact Us Help Search Canada Site
Home Centers & Labs Publications Guidelines A-Z Index
Check the help on Web Accessibility features Child Health Adult Health Seniors Health Surveillance Health Canada
Public Health Agency of Canada
Home : Publications : The Management of Viral Hepatitis : References

The Management of Viral Hepatitis

Canadian Association for Study of the Liver

CASL - ACEF

Proceedings of a consensus conference held in
Montreal, Quebec in March 1999

REFERENCES

  1. Wong WW, Minuk GY. A cross-sectional seroepidemiologic survey of chronic hepatitis B virus infections in Southeast Asian immigrants residing in a Canadian urban centre. Clin Invest Med 1994 17:443-7

  2. Sweet LE, Brown MG, Lee SH, Liston RM, MacDonald MA, Forward KR. Hepatitis B prenatal screening survey, Nova Scotia, 1990-1991. Can J Public Health 1993 84:279-82

  3. Chernesky MA, Blajchman MA, Castriciano S, Basbaum J, Spivak C, Mahony JB. Analysis of a pregnancy-screening and neonatal-immunization program for hepatitis B in Hamilton, Ontario, Canada, 1977-1988. J Med Virol 1991 35:50-4

  4. Delage G, Montplaisir S, Remy-Prince S, Pierri E. Prevalence of hepatitis B virus infection in pregnant women in the Montreal area. Can Med Assoc J 1986 134:897-901

  5. Minuk GY, Nicolle LE, Postl B, Waggoner JG, Hoofnagle JH. Hepatitis virus infection in an isolated Canadian Inuit (Eskimo) population. J Med Virol 1982 10:255-64

  6. Baikie M, Ratnam S, Bryant DG, Jong M, Bokhout. Epidemiologic features of hepatitis B virus infection in Northern Labrador. Can Med Assoc J 1989 141:791-5

  7. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995 21:77-82

  8. Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988 8:1130-3

  9. Gupta S, Govindarajan S, Fong TL, Redeker AG. Spontaneous reactivation in chronic hepatitis B patterns and natural history. J Clin Gastroenterol 1990 12:562-8

  10. Fattovich G, Brollo L, Alberti A, Realdi G, Pontisso P et al. Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis. Liver 1990 10:141-6.

  11. Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus infection. Incidence, predisposing factors and etiology. J Hepatol 1990 10:29-34.

  12. Lok AS, Lai CL, Wu PC, Leung EK, Lam T. Spontaneous hepatitis B e antigen to antibody serconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987 92:1839-43

  13. Fattovich G, Rigge M, Brollo L, Pontisso P, Noventa F, Guido M et al. Clinical, virologic and histologic outcome following serconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986 6:167-72

  14. de Franchis R, Meucci G, Vecchi M, Tatarella M,colombo M, Del Ninno, Rumi MG et al. The natural history of symptomatic hepatitis B surface antigen carriers. Ann Int Med 1993 118:191-4

  15. Fattovich G, Guistina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 1998 93:896-900.

  16. Koh KC, Lee HS, Kim CY, Universal emergence of precore mutant hepatitis B virus along with seroconversion to anti-HBe irrespective of subsequent activity of chronic hepatitis B. Korean J intern Med 1994 9: 61-6

  17. Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994 21:656-66

  18. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992 103:1630-5

  19. Fattovich G, Brollo L, Guistina G, Noventa F, Pontisso P Alberti A et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991 32:194-8

  20. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet. 1981 2(8256):1129-33.

  21. Lai CL, Chien RN, Leung NW, Chang TT, Guan R Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998 339:61-8.

  22. Heathcote J, Schalm S, Ciancara J, Farrell G, Feinman V, Sherman M et al. Lamivudine and Intron A combination treatment in chronic hepatitis B infection. Hepatology 1998, 28 Suppl:43.

  23. Schiff E, Karayalcin S, Grimm I, Perrillo R Dinestag J, Hasa P et al. A placbo-controlled study of lamivudine and interferon alpha 2 b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 1998 28 Suppl:43.

  24. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998 27:1670-7

  25. Di Bisceglie AM, Fong TL, Fried MW, Swain MG, Baker B, Korenman J et al. A randomized controlled trial of recombinant alpha interferon therapy for chronic hepatitis B. Am J Gastroenterology 1993 88:1887-92

  26. Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomized controlled trial of recombinant interferon alpha-2 in Chinese patients with chronic hepatitis B infection. Lancet 1988 2:298-302

  27. Lai CL, Lok AS, Lin HJ, Wu PC, Yeoh EK, Yeung CY. Placebo-controlled trial of recombinant alpha-2 interferon in Chinese HBsAg-carrier children. Lancet 1987 2:877-80

  28. Krogsgaard K, Bindslev N, Christensen E, Craxi A, Schlichting P, Schalm S et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep). J Hepatol 1994 21:646-55

  29. Thomas HC, Lok AS, Carreno V, Farrell G, Tanno H, Perez V, et al. Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. The International Hepatitis Trial Group. J Viral Hepat 1994 1(2):139-48

  30. Brook MG, McDonald JA, Karayiannis P, Caruso L, Forster G, Harris JR, Thomas HC. Randomized controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 1989 30:1116-22

  31. Wong DK, Yim C, Naylor CD, Chen E, Sherman M, Vas S et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995 108:165-71

  32. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989 10:761-3

  33. Lok AS, Ghany MG, Watson G, Ayola B. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Viral Hepat 1998 5:171-8

  34. Fattovich G, McIntyre G, Thursz M, Colman K, Giuliano G, Alberti A et al. Hepatitis B virus precore/core variation and interferon therapy. Hepatology. 1995 22:1355-62.

  35. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999 29:889-96

  36. Picardi M, Selleri C, De Rosa G, Raiola A, Pezzullo L, Rotoli B. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 199 21:1267-9

  37. Brind AM, et al. Nucleoside analogue therapy in fibrosing cholestatic hepatitis--a case report in an HBsAg positive renal transplant recipient. Liver. 1998 18:134-9.

  38. Lok AS, Lindsay I, Scheuer PJ, Thomas HC. Clinical and histological features of delta infection in chronic hepatitis B virus carriers. J Clin Pathol 1985 38:530-3

  39. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994 330:88-94

  40. Perrillo R, Tamburro C, Regenstein F, Balart L Bodenheimer H, Silva M et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995 109:908-16

  41. Lin CY Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 1995 47:225-30.

  42. Conjeevaram HS, Hoofnagle JH, Austin HA, Park Y, Fried MW, Di Bisceglie AM. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology 1995 109:540-6

  43. Bortolotti F, Faggion S, Con P. Natural history of chronic viral hepatitis in childhood. Acta Gastroenterol Belg 1998 61:198-201.

  44. Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998 114:988-95

  45. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 1998 143:2493-503

  46. Bernier L, Willems B, Delage G, Murphy DG. Indentification of numerous hepatitis C virus genotypes in Montreal, Canada. J Clin Microbiol 1996 34:2815-8

  47. Murphy DG, Willems B, Delage G, Fenyves D, Huet PM, Marleau D et al. Hepatitis C virus genotypes in patients and blood donors. Can Commun Dis Rep 1995 21:129-32

  48. Altamirano M, Delaney A, Wong A, Maronstenmaki J, Pi D. Identification of hepatitis C virus genotypes among hospitalized patients in British Columbia, Canada. J Infect Dis 1995 171:1034-8

  49. Andonov A, Chaudhari RK. Genotyping of Canadian hepatitis C virus isolates by PCR. J Clin Microbiol 1994:2031-4.

  50. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995 332:1463-6

  51. Pol S Fontaine H Carnot F Zylberberg H, Berthelot P Brechot C Nalpas B. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol 1998 29:12-9

  52. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998 28:1687-95.

  53. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998 28:805-9

  54. Pol S, Lamothe B, Thi NT, Thiers V, Carnot F, Zylberberg H et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998 28:945-50

  55. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998 27:1717-22

  56. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996 23:1334-40

  57. Roudot-Thoraval F, Bastie A, Pawlotsky JM Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997 26:485-90

  58. Sobesky R, Mathurin P, Charlotte F, Moussalli J Olivi M, Vidaud M et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999 116:378-86

  59. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999 340:1228-33.

  60. Mathurin P, Moussalli J, Cadranel JF, Thibault V Charlotte F, Dumouchel P, et al Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998 27:868-72

  61. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997 349:825-32

  62. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997 112:463-72.

  63. Piazza M,. Sagliocca L, Tosone G, Guadagnino V, Stazi MA, Orlando R et al. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med. 1997 157:1537-44.

  64. Kao JH, Liu CJ, Chen PJ, Chen W, Hsiang SC, Lai MY, Chen DS. Interspousal transmission of GB virus-C/hepatitis G virus: a comparison with hepatitis C virus. J Med Virol. 1997 53:348-53.

  65. Comandini UV, Tossini G, Longo MA, Ferri F, Cuzzi G, Noto P Sporadic hepatitis C virus infection: a case-control study of transmission routes in a selected hospital sample of the general population in Italy. Scand J Infect Dis 1998 30(1):11-5

  66. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). : Ann Intern Med. 1991 115:764-8.

  67. Thomas DL, Zenilman JM, Alter HJ, Shih JW, Galai N, Carella AV, Quinn TC. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis. 1994 169:990-5.

  68. Akahane Y Kojima M, Sugai Y, Sakamoto M, Miyazaki Y, Tanaka T, et al. Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med. 1994 120:748-52.

  69. Caporaso N, Ascione A, Stroffolini T. , Spread of hepatitis C virus infection within families. Investigators of an Italian Multicenter Group. J Viral Hepat 1998 5:67-72

  70. Ohto H, Terazawa S, Sasaki N, Sasaki N, Hino K, Ishiwata C et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med. 19947 330:744-50.

  71. Zanetti AR, Tanzi E, Romano L, Zuin G, Minola E, Vecchi L, Principi N. A prospective study on mother-to-infant transmission of hepatitis C virus. Intervirology. 1998 41:208-12.

  72. Meisel H, Reip A, Faltus B, Lu M, Porst H Wiese M et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet. 1995 345(8959):1209-11.

  73. Thomas DL, Villano SA, Riester KA, Hershow R, Mofenson LM, Landesman SH et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis. 1998 177:1480-8.

  74. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997 127:875-81

  75. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998 351(9096):83-7.

  76. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998 339:1485-92.

  77. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet. 1998 352(9138):1426-32.

  78. Laursen AL, Scheibel E, Ingerslev J, Clausen NC, Wantzin P, Ostergaard L et al. Alpha interferon therapyin Danish hemophliac patients with chronic hepatitis C: results of a randomized controlled open label study comparing two different maintenance regimens following standard interferon alpha 2b treatment. Haemophilia 1998 4:25-32.

  79. Rumi MG, Santagostino E, Morfini M, Gringeri A, Tagariello G, Chistolini A et al. A multicenter controlled randomized open label trial of interferon alpha 2b treatment of anti-human immunodeficiency virus-negative hemophiliac patients with chronic hepatitis C. Hepatitis Study Group of the Italian Hemophilia Centers. Blood 1997 89:3529-33.

  80. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998 339:1493-9

  81. Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ Reddy KR et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998 27:1136-43

  82. Garcia-Monzon C, et al. Chronic hepatitis C in children: a clinical and immunohistochemical comparative study with adult patients. Hepatology. 1998 28:1696-701.

  83. Iorio R, Pensati P, Porzio S, Fariello I, Guida S, Vegnente A. Lymphoblastoid interferon alfa treatment in chronic hepatitis C. Arch Dis Child. 1996 74:152-6.

  84. Bortolotti F, Giacchino R, Vajro P, Barbera C, Crivellaro C, Alberti A et al. Recombinant interferon-alfa therapy in children with chronic hepatitis C. Hepatology. 1995 22:1623-7.

  85. Viladomiu L, Genesca J, Esteban JI, Allende H, Gonzalez A, Lopez-Talavera JC et al. Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial. Hepatology 1992 15:767-9

  86. Hwang SJ, Lee SD, Chan CY, Lu RH, Lo KJ. A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol. 1994 21:831-6.

  87. Lampertico P, Rumi M, Romeo R, Craxi A, Soffredini R, Biassoni D, Colombo M. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C. Hepatology. 1994 19:19-22.

  88. Crespo J, Lozano JL, de la Cruz F, Rodrigo L, Rodriguez M, San Miguel G et al. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol 1994 89:1147-51

  89. Chan CY, Lee SD, Wu JC, Hwang SJ, Wang YJ, Huang YS, Lo KJ. Superinfection with hepatitis C virus in patients with symptomatic chronic hepatitis B. Scand J Infect Dis 1991 23:421-4

  90. Sato S, Fujiyama S, Tanaka M, Yamasaki K, Kuramoto I, Kawano S et al. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol 1994 21:159-66

  91. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998 27:1435-40.

  92. Fong TL, Di Bisceglie AM, Waggoner JG, Banks SM, Hoofnagle JH. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology 1991 14:64-7

  93. Benvengu L, Fattovich G, Noventa F, Tremolada F, Chemello L, Cecchetto A, Alberti A. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 1994 74:2442-8

  94. Pontisso P, Ruvoletta MG, Fattovich G, Chemello L, Gallorini, F, Ruol A, Alberti A. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993 105:1529-33

  95. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998 28:27-33

  96. Chiba T, Matsuzaki Y, Abei M, Shoda J, Aikawa T, Tanaka N, Osuga T. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 1996 31:552-8

  97. Weltman MD, Brotodihardjo A, Crewe EB, Farrell GC, Bilous M, Grierson JM, Liddle C. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995 2:39-45

  98. Hess G, Rossol S, Voth R, Gerken G, Ramadori G, Drees N, Meyer zum Buschenfelde KH. Treatment of patients with chronic type B hepatitis and concurrent human immunodeficiency virus infection with a combination of interferon alpha and azidothymidine: a pilot study. Digestion 1989 43:56-9

  99. Macias J, Pineda JA, Leal MA, Garcia-Pesquera F, DelgadoJ, Gallardo JA et al. Influence of hepatitis C infection on the mortality of antiretroviral-treated patients with HIV disease. Eur J Clin Microbiol Infect Dis 1998 17:167-70.

  100. Ghany MG, Leissinger C, Lagier R, Sanchez-Pescador R, Lok AS. Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. Dig Dis Sci 1996 41:1265-72.

  101. Soriano V, Garcia-Samaniego J, Bravo R, Castro A Odriozola PM, Gonzalez J et al. Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients. HIV-Hepatitis Spanish Study Group. J Infect 1995 31:9-13

  102. Mauss S, Klinker H, Ulmer A, Willers R, Weissbrich B Albrecht H et al. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection 1998 26:16-9

  103. Mauss S, Heintges T, Adams O, Albrecht H, Niederau C, Jablonowski H. Treatment of chronic hepatitis C with interferon-alpha in patients infected with the human immunodeficiency virus. Hepatogastroenterology 1995 42:528-34

  104. Boyer N, Marcellin P, Degott C, Degos F, Saimot AG, Erlinger S, Benhamou JP. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comite des Anti- Viraux. J Infect Dis 1992 165:723-6

  105. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L. Lanier AP. Hepatitis B related sequelae. Prospective study of 1400 hepatitis B surface antigen positive Alaskan native carriers. Arch Intern Med 1990 150: 1051-1054.

  106. Villeneuve JP, Desrochers M, Infante-Rivard C, Willems B, Raymond G, Bourcier M et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen- positive carriers in Montreal. Gastroenterology 1994 106:1000-5

  107. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995 22:432-8.

  108. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985 56:918-28.

  109. Heyward WL, Lanier AP, McMahon BJ, Fitzgerald MA, Kilkenny S, Paprocki TR. Early detection of primary hepatocellular carcinoma. Screening for primary hepatocellular carcinoma among persons infected with hepatitis B virus. JAMA. 1985 254:3052-4.

  110. Franks AL, Berg CJ Kane MA, Browne BB, Sikes RK, Elsea WR, Burton AH. Hepatitis B virus infection among children born in the United States to Southeast Asian refugees. N Engl J Med. 1989 321(19):1301-5.

  111. Hurie MB, Mast EE, Davis JP. Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. Pediatrics. 1992 89:269-73.

  112. Mahoney FJ, Lawrence M, Scott C, Le Q, Lambert S, Farley TA Continuing risk for hepatitis B virus transmission among Southeast Asian infants in Louisiana. Pediatrics. 1995 96:1113-6.

  113. Prevention of Transmission of hepatitis B. Can Med Assoc J. 1998 159:71-6.

  114. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998 338:286-90.

  115. Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998 27:881-6

  116. Preventing hepatitis A infections. National Advisory Committee on Immunization statement. Laboratory Centre for Disease Control. Can Fam Physician 1995 41:1222-8

  117. Linnen J, Wages J Jr, Zhang-Keck ZY, Fry KE Krawczynski KZ, Alter H et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996 271(5248):505-8

  118. Alter HJ, Nakatsuji Y, Melpolder J, Wages J Wesley R, Shih JW, Kim JP. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997 336:747-54

  119. Alter MJ, Gallagher M, Morris TT, Moyer LA, Meeks EL Krawczynski K et al. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. Sentinel Counties Viral Hepatitis Study Team. N Engl J Med 1997 336:741-6

  120. Frider B, Sookoian S, Castano G, Gonzalez J, Flichman D, Viudez P et al.. Detection of hepatitis G virus RNA in patients with acute non-A-E hepatitis. J Viral Hepat 1998 5:161-4

  121. Pessoa MG, Terrault NA, Detmer J, Kolberg J Collins M, Hassoba HM, Wright TL. Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic. Hepatology 1998 27:877-80

  122. Berenguer M, Terrault NA, Piatak M, Yun A, Kim JP, Lau JY et al. Hepatitis G virus infection in patients with hepatitis C virus infection undergoing liver transplantation. Gastroenterology. 1996 111:1569-75.

  123. Naoumov NV, Petrova EP, Thomas MG, Williams R. Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet 1998 352:195-97

  124. Simmonds P, Davidson F, Lycett C, Prescott LE, MacDonald DM, Ellender J et al. Detection of a novel DNA virus (TTV) in blood donors and blood products. Lancet 1998 352:191-5

  125. Hsieh Sy, Wu YH, Ho YP, Tsao KC, Yeh CT, Liaw YF. High prevalence of TT virus infection in healthy children and adults and in patients with liver disease in Taiwan. J Clin Microbiol. 1999 37:1829-31

[Previous] [Table of Contents]

 
Last Updated: 2000-06-26 Top
Important Notices